Ivan Kairatov is a distinguished figure in the biopharma industry, renowned for his expertise in tech and innovation within the field. With a robust background in research and development, Ivan has substantially influenced advancements in cellular therapies and drug development. Today, we delve
A groundbreaking study from Arizona State University (ASU) has discovered remarkable insights about a potentially new healing process prompted by necrosis, the premature death of cells. This unexpected phenomenon, observed in fruit flies known for their regenerative capabilities, may have profound
Artis Biosolutions' acquisition of Landmark Bio marks a strategic move designed to bolster cell and gene therapy (CGT) manufacturing capabilities. Landmark Bio, founded by Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva, has been a key
The medical landscape has been witnessing a groundbreaking shift with the advent of novel therapies aimed at tackling some of the most challenging conditions. One such development is the Phase 1/2 clinical trial of Cabaletta Bio's CAR T-cell therapy, rese-cel (resecabtagene autoleucel),
The recent resignation of Peter Marks as the head of the FDA's Center for Biologics Evaluation and Research (CBER) marks a significant moment for the cell and gene therapy industry. His departure has sparked widespread discussion about the future direction of the regulatory landscape and its
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. He joins us today to discuss Ori Biotech’s new Preferred Partner Network (PPN), the collaboration with various organizations, and the impacts on cell therapy d
